ALB and acute kidney injury: The early versus standard initiation of terlipressin for HRS-AKI in with ACLF patients study, a randomized controlled trial, evidenced how early initiation of terlipressin in patients with ACLF and AKI, compared with standard initiation at 48 h and no improvement in renal function despite 12 h of volume expansion with albumin, achieved higher rates of complete recovery of renal function at 7 days (68.6% vs 40%; P = .03), lower 28-day mortality rates (40% vs 65.7%; P = .031) and a significant reduction in ACLF stage [47].